Child Examinations | North Tonawanda, NY

After Hour Nurse Advice Lines
phone iconPhone: (716) 807-7337
phone iconFax: (716) 213-4400
Receive our Health e-Newsletter


News for Healthier Living

Antibody-Drug Conjugate Achieves High Response Rates as Frontline Treatment in Aggressive, Rare Blood Cancer

Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) had a complete response, according to new data from the Phase I/II multicenter international CADENZA trial led by researchers at The University of Texas MD Anderson Cancer Center.

February 11, 2026


February 23 2026

February 22 2026

February 21 2026

February 20 2026

February 19 2026

February 18 2026

February 17 2026

February 16 2026

February 15 2026

February 14 2026

February 13 2026

February 12 2026

February 11 2026

February 10 2026